Culture

Cancer survivors face elevated heart disease risk, study finds

A new study has found that about 35% of Americans with a cancer history had an elevated risk of cardiovascular disease in the next decade, compared with about 23% of those who didn't have cancer.

Based on a risk calculator that estimates a person's 10-year chances of developing heart disease or stroke, researchers from The Ohio State University found that the average estimated 10-year risk for a cancer survivor was about 8%, compared to 5% for those who didn't have a history of cancer.

The new study appears in the journal PLOS ONE.

"We know that obesity, cancer and cardiovascular disease share some common risk factors, and in addition to those shared risk factors, cancer patients also receive treatments including radiation and chemotherapy that can affect their cardiovascular health - we call that cardiotoxicity," said lead researcher Xiaochen Zhang, a PhD candidate in Ohio State's College of Public Health.

But those risks may be underestimated or poorly understood, leading Zhang and fellow researchers to urge steps to boost recognition among health care providers and their patients.

"The good news is that we're getting really good at treating cancer and we have more survivors, but we need to start thinking more carefully about the non-cancer risks following a diagnosis, one of which is cardiovascular disease," said study senior author Ashley Felix, an associate professor of epidemiology at Ohio State.

"We don't want people to survive cancer only to die prematurely of heart disease or stroke, so we need to make sure that cancer patients, and their health care team, are aware of this increased risk."

The data used in the study comes from the National Health and Nutrition Examination Survey conducted by the Centers for Disease Control and Prevention. The nationally representative sample of people surveyed from 2007 to 2016 should provide a good picture of the elevated risk for cancer survivors in the U.S., the researchers said.

For this analysis, they examined data provided by 15,095 adults aged 40 to 79 years with no history of cardiovascular disease. Almost 13% reported a history of cancer.

One of the strengths of this research is the large study size, which allowed for analysis based on type of cancer and by age group. Survivors of testicular, prostate, bladder and kidney cancers had particularly high 10-year cardiovascular disease risk, as did those in their 60s.

When the researchers compared individual cardiovascular disease risk factors by cancer status, they found that older age, higher systolic blood pressure and a personal history of diabetes were more common in the cancer survivors.

Looking forward, it's important that researchers and health care providers keep their eyes on the growing number of cancer survivors, including younger adults, Felix said. Almost 17 million Americans live with a cancer diagnosis, a number that is expected to grow to 26 million by 2040.

"If we continue to see the increasing incidence of cancer among younger adults, we can expect to see a larger burden of cardiovascular disease among those individuals - our future studies need to go in that direction," she said.

Added Zhang, "The good news is that those younger individuals have a lot of time to make lifestyle changes that could move their cardiovascular risk in a positive direction.

"In addition to monitoring cancer survivors carefully for cardiovascular disease - and making them aware of the elevated risk - health care providers have the opportunity to guide patients toward interventions that can lower their risk," she said.

There's also potential for developing a risk-assessment tool that specifically takes cancer survivorship into account - which would allow for more precise assessments for that population, the researchers said.

Credit: 
Ohio State University

A sturdier spike protein explains the faster spread of coronavirus variants

image: This model shows the structure of the spike protein in its closed configuration, in its original D614 form (left) and its mutant form (G614). In the mutant spike protein, the 630 loop (in red) stabilizes the spike, preventing it from flipping open prematurely and rendering SARS-CoV-2 more infectious.

Image: 
Bing Chen, PhD, Boston Children's Hospital

BOSTON - March 16, 2021 - The fast-spreading UK, South Africa, and Brazil coronavirus variants are raising both concerns and questions about whether COVID-19 vaccines will protect against them. New work led by Bing Chen, PhD, at Boston Children's Hospital analyzed how the structure of the coronavirus spike proteins changes with the D614G mutation -- carried by all three variants -- and showed why these variants are able to spread more quickly. The team reports its findings in Science (March 16, 2020).

Chen's team imaged the spikes with cryo-electron microscopy (cryo-EM), which has resolution down to the atomic level. They found that the D614G mutation (substitution of in a single amino acid "letter" in the genetic code for the spike protein) makes the spike more stable as compared with the original SARS-CoV-2 virus. As a result, more functional spikes are available to bind to our cells' ACE2 receptors, making the virus more infectious.

Preventing spikes' shape change

In the original coronavirus, the spike proteins would bind to the ACE2 receptor and then dramatically change shape, folding in on themselves. This enabled the virus to fuse its membrane with our own cells' membranes and get inside. However, as Chen and colleagues reported in July 2020, the spikes would sometimes prematurely change shape and fall apart before the virus could bind to cells. While this slowed the virus down, the shape change also made it harder for our immune system to contain the virus.

"Because the original spike protein would dissociate, it was not good enough to induce a strong neutralizing antibody response," says Chen.

When Chen and colleagues imaged the mutant spike protein, they found that the D614G mutation stabilizes the spike by blocking the premature shape change. Interestingly, the mutation also makes the spikes bind more weakly to the ACE receptor, but the fact that the spikes are less apt to fall apart prematurely renders the virus overall more infectious.

"Say the original virus has 100 spikes," Chen explains. "Because of the shape instability, you may have just 50 percent of them functional. In the G614 variants, you may have 90 percent that are functional, so even though they don't bind as well, the chances are greater that you will have infection."

Chen proposes that redesigned vaccines incorporate the code for this mutant spike protein. The more stable spike shape should make any vaccine based on the spike (as are the Moderna, Pfizer, and Johnson & Johnson vaccine) more likely to elicit protective neutralizing antibodies, he says.

Future direction: A drug to block coronavirus entry

Chen and his colleagues are further applying structural biology to better understand how SARS-CoV-2 binds to the ACE2 receptor, with an eye toward therapeutics to block the virus from gaining entry to our cells.

In January, the team showed in Nature Structural & Molecular Biology that a structurally-engineered "decoy" ACE2 protein binds the virus 200 times more strongly than the body's own ACE2. The decoy potently inhibited the virus in cell culture, suggesting it could be an anti-COVID-19 treatment. Chen is now planning to advance this research into animal models.

Credit: 
Boston Children's Hospital

Declining caribou population victim of ecological chain reaction

image: A team of researchers has determined the declining caribou population is part of a natural chain reaction from forest harvesting which can attract predators and competition for food.

Image: 
Caribou Monitoring Unit

A new study comparing decades of environmental monitoring records has confirmed that Canada's caribou are not faring as well as other animals like moose and wolves in the same areas--and also teased out why.

The study used 16 years of data to examine changes in vegetation, moose, wolves and caribou.
"Caribou are declining across Canada and have been recently lost in the Lower 48 States," says Melanie Dickie, a doctoral student with UBC Okanagan's Irving K. Barber Faculty of Science.

"Understanding why caribou are declining is the first step to effectively managing the species--it tells us which parts of the issue we can target with management actions and how that might help caribou."

Dickie, along with fellow UBCO researchers Dr. Clayton Lamb and Dr. Adam Ford, describe the decline in caribou populations as an ecological puzzle. Typically, there are multiple factors, all changing at once, making it hard to identify how the pieces fit together. Factors such as predation from wolves and other large carnivores, increasing moose and deer populations, and habitat alteration through resource extraction and wildfires all play a part. The study aimed to sort out the roles each of these play in caribou population declines.

Once land is cleared by either wildfire or harvesting, the mature forest transforms into more productive early seral forage. With the tree canopy removed, there is a significant increase in sunlight, allowing understory plants to thrive. These plants provide food that benefits moose, deer and their predators. These predators then have a spillover effect on the rarer caribou, creating apparent competition between moose and caribou.

"Changes in primary productivity have the potential to substantially alter food webs, with positive outcomes for some species and negative outcomes for others," Dickie explains. "Understanding the environmental context and species interactions that give rise to these different outcomes is a major challenge to both theoretical and applied ecology."

To establish the link between habitat alteration and primary productivity, the researchers first examined satellite imagery to show a link between logging and new vegetation growth. They then used data on moose, caribou and wolf numbers to compare the leading hypotheses on how changes in vegetation influence these populations. The analysis was conducted across a 598,000-square kilometre area located in the boreal shield and boreal plains of western Canada.

Ultimately, the researchers determined that lower caribou populations were a victim of an ecological chain reaction. Caribou have a lower population growth rate relative to moose, making them more susceptible to landscape changes.

"We found that increased deciduous vegetation on the landscape, which moose like to eat, increased moose populations, which increased wolves, and in turn, means declining caribou," Dickie says. "We also found that human land use, like forestry, significantly increased vegetation productivity, suggesting that these kinds of land uses are leading to caribou declines via changes to predators and prey."

Caribou conservation will be a defining point for Canada in the 21st century, adds Dr. Lamb, a Liber Ero Fellow at UBCO. Caribou highlight an unresolved tension between land stewardship, wildlife conservation and resource extraction. Further, as caribou populations continue to decline, Indigenous Peoples are forced to grapple with mounting threats to food security, cultural traditions, and infringed treaty rights.

"We can't attribute caribou declines to just one factor or another," he says. "But understanding the relative importance of these factors, and how they interact, can help us understand how we can manage caribou populations in the face of continued climate change and land use."

Credit: 
University of British Columbia Okanagan campus

Christmas Island reptile-killer identified

image: One of the Australian-native, critically endangered lizard species: Lister's gecko.

Image: 
Parks Australia.

Native reptile populations on Christmas Island have been in severe decline with two species, Lister's gecko and the blue-tailed skink, entirely disappearing from the wild. While previously the main driver for this decline is likely predation by invasive species and habitat destruction, a silent killer is now threatening to wipe the species out entirely.

Those bred in captivity on the Australian Territory in the Indian Ocean have also been mysteriously dying, leaving the two species - which number only around 1000 each - in danger of extinction. Veterinary scientists from the University of Sydney, the Australian Registry of Wildlife Health and the Taronga Conservation Society Australia have now discovered the cause of these deaths: a bacterium, Enterococcus lacertideformus (E. lacertideformus).

The bacterium was discovered in 2014 after captive reptiles presented with facial deformities and lethargy, and some even died. Samples were collected and analysed using microscopy and genetic testing.

The researchers' findings, published in Frontiers in Microbiology, will inform antibiotic trials on the reptiles to see if the infection can be treated.

The bacterium grows in the animal's head, then in its internal organs, before eventually causing death. It can be spread by direct contact - including through reptiles' mouths, or via reptiles biting one another - often during breeding season fights.

"This means that healthy captive animals need to be kept apart from infected ones and should also be kept away from areas where infected animals have been," said Jessica Agius, co-lead researcher and PhD candidate in the Sydney School of Veterinary Science.

Ms Agius and the research team not only identified the bacterium, they decoded its genetic structure using whole genome sequencing.

Specific genes were identified that are likely to be associated with the bacterium's ability to infect its host, invade its tissues and avoid the immune system.

"We also found that the bacterium can surround itself with a biofilm - a 'community of bacteria' that can help it survive," Ms Agius said.

"Understanding how E. lacertideformus produces and maintains the biofilm may provide insights on how to treat other species of biofilm-forming bacteria."

The search of the genetic code suggested that the killer bacterium was susceptible to most antibiotics.

Professor David Phalen, research co-lead and Ms Agius' PhD supervisor, said: "This suggests that infected animals might be successfully treated. That's what we need to determine now."

In another effort to protect the endangered reptiles on Christmas Island, a population of blue-tailed skinks has been established on the Cocos Islands. Ms Agius played a critical role in the translocation, testing reptiles on the Cocos Islands to make sure that they were free of E. lacertideformus.

"It's critical we act now to ensure these native reptiles survive," Ms Agius said.

Credit: 
University of Sydney

Researchers develop acid-sensitive nanoparticles as new treatment for pancreatic cancer

The research team led by Prof. YANG Lihua from Hefei National Laboratory for Physical Sciences at the Microscale, School of Chemistry and Materials Science of the University of Science and Technology of China (USTC) of the Chinese Academy of Sciences proposed nanomicelles composed solely of macromolecules as a new approach for treating pancreatic tumor. The study was published in ACS Applied Materials & Interfaces.

Host dense peptides (HDP) is a part of the innate immunity of eukaryotic organism. It helps the host fence back attack by microbes through disrupting cellular membrane integrity. Inspired by HDP, membrane-disruptive macromolecules are designed with two most HDP's common structural characteristics (cationic and amphipathic) to realize similar membrane-disrupting function so that drug-resistant cancer cells can be efficiently eliminate. The onset of drug resistance is delayed after repeat treatment, suggesting the potential for addressing the cancer resistance issue.

Despite these advantages, membrane-disruptive macromolecules normally cannot distinguish cancerous from normal cells. How to make membrane-disruptive macromolecules preferentially active to cancerous cells over normal cells is a significant challenge.

In this study, the researchers used an acid-sensitive, membrane-disruptive micelle (M-14K) as the model for such nanoparticles.

This long-circulating nanoparticle showed acid-activated cytotoxicity indiscriminately to both cancerous and fibroblast cells, which is realized by acid-activatable disruption of cellular membrane integrity. The ability of such nanoparticles to penetrate the stromal barrier and eliminate the sheltered cancer cells was verified both in vitro using three-dimensional (3D) cell spheroids and in vivo using mouse models bearing BxPC-3 tumors.

Notably, through animal experiments, the researchers found that the expression of extracellular matrix components was significantly suppressed, the tumor tissue was transformed into a less dense structure, and stroma was remodeled, without promoting tumor metastasis.

Using acid-responsive nanoparticles composed solely of membrane-disruptive macromolecules, stroma remodeling and cancerous cells elimination can be realized simultaneously. This approach may open a new avenue for the development of efficacious drugs inhibiting pancreatic tumor growth and metastasis.

What makes pancreatic tumor hard to cure is the dense stromal barriers sheltering cancerous cells. The penetration of drugs is hindered. To promote the infiltration of therapeutics, an adjuvant is used prior to gemcitabine to remodel the stroma. Nevertheless, this widely studied strategy may raise the risk of tumor metastasis and tumor cells' resistance to drugs.

Credit: 
University of Science and Technology of China

Serious vision impairment declines among older Americans between 2008 and 2017

TORONTO, ON - American adults 65 years old and older have better vision than that age group did nearly a decade ago, according to a recent study published in the journal Ophthalmic Epidemiology.

In 2008, 8.3% of those aged 65 and older in the US reported serious vision impairment. In 2017 that number decreased to 6.6% for the 65-plus cohort. Put another way: if vision impairment rates had remained at 2008 levels, an additional 848,000 older Americans would have suffered serious vision impairment in 2017.

"The implications of a reduction in vision impairment are significant," says the study's first author, University of Toronto pharmacy student, ZhiDi (Judy) Deng.

"Vision problems are a major cause of age-related disability, and serious vision impairment can increase the risk of falls and fractures and undermine quality of life. Moreover, the cost of vision impairment to the US economy is in the tens of billions of dollars. We need to determine how to maintain this positive trajectory into the next decade and beyond."

Racial/Ethnic disparities in vision health decreased

For every year between 2008 and 2017, serious vision impairment was more prevalent among Black and Hispanic respondents aged 65 and older than among non-Hispanic White respondents; however, these racial/ethnic health disparities appear to be narrowing.

Black and Hispanic Americans over 65 showed greater reductions in vision impairment across the decade compared to Non-Hispanic White Americans, with a 27% decline in serious vision impairment among Black respondents and a 24% decline among Hispanic Americans. Non-Hispanic White Americans showed the smallest decline in serious vision impairment at 13%.

"The narrowing of racial/ethnic disparities in vision related problems during this period may be attributable, in part, to the implementation of the Affordable Care Act which led to a large increase in the percentage of insured Hispanics and Black Americans," says Deng.

"While it is heartening to see the racial disparities improving over the decade, targeted outreach and improved access to affordable vision care for racialized groups is still urgently needed to effectively eliminate the gap."

The greatest improvement in vision occurred in those aged 85 and older

The observed decade decline in vision problems was propelled by a 26% decrease in the odds of vision impairment among those aged 85 and older, and a 16% decline among those aged 75-84 when adjustments were made for age, sex, and race/ethnicity. In contrast, the 65 to 74-year-old cohort had a much more modest improvement compared to their 2008 counterparts, experiencing only a 2.6% decline over the decade.

"Although a 21% decline in the odds of vision impairment over a 10-year period is truly phenomenal, we cannot assume this trend will continue at the same pace," says senior author, Esme Fuller Thomson, director of University of Toronto's Institute of Life Course and Aging and professor at the Factor-Inwentash Faculty of Social Work, the Department of Family & Community Medicine and the Bloomberg Faculty of Nursing.

"The very small gains made by those currently aged 65 to 74 over the past decade suggest that as the Baby Boom cohort ages into their late 70s and 80s, the downward trend in the future may be much less steep than that seen from 2008 to 2017."

Vision improvements among women drives change

Women account for nearly two-thirds of global blindness. In this study, women had a higher prevalence of vision impairment compared to men, but this gap narrowed over the decade. The rate of decline in the odds of impairment over the decade was consistently greater for women (21%) than for men (9%). It is unclear why the rate of improvement differs by gender, but previous research suggest women are more likely than men to visit eye care professionals, which may contribute to these findings.

Causes remain a medical mystery

The observed downward trajectory in vision problems among older adults is in keeping with previous studies using smaller samples in the United States and Europe, but the reason for such a dramatic decrease remains a medical mystery.

The study's authors hypothesize several potential causes for the observed improvements, including advances in medical interventions for vision problems, better management of comorbid health conditions such as diabetes, cohort differences in lifelong access to vaccinations and antibiotics, universal folic acid supplementation, decreases in periodontitis, and improvements in air pollution, including lower life-time exposure to lead due to the phase-out of leaded gasoline. However, the design of this study and earlier research do not provide definitive insight into the causes of the observed positive trend in the prevalence of serious vision problems.

The study was based on 10 consecutive waves of the American Community Survey (2008-2017) which engaged a nationally representative sample of approximately half a million American respondents aged 65 and older annually, including those who lived in institutions such as long-term care homes, and those who were living in the community. The question on vision impairment was "Is this person blind or does he/she have serious difficulty seeing even when wearing glasses?"

"It is truly remarkable that there would have been an additional 848,000 older Americans with serious vision impairment in 2017 if the rates had remained at 2008 levels," says Fuller-Thomson. "We need more research to understand why these trends are occurring."

Credit: 
University of Toronto

High speed air hand dryers spread contamination more than paper towels

NEW YORK (March 17, 2021) -- High speed air dryers not only leave more contamination on poorly washed hands compared to paper towels, but during hand drying, they can also spread germs onto clothing, ultimately transferring more bacteria to other surfaces, according to a study published today in Infection Control & Hospital Epidemiology, the journal of the Society for Healthcare Epidemiology of America.

Past research has shown recommended handwashing practices for healthcare workers are often not followed with average adherence of 40%. To better understand the impact of hand drying in hand hygiene, researchers conducted an experiment to learn the role of different hand drying methods in spreading germs from poorly washed hands beyond the restroom.

For the study, volunteers sanitized their hands with 70% alcohol disinfectant, dipped them in a nonharmful viral solution, shook them off, and then dried them either using an air dryer or paper towels. During experiment, volunteers wore an apron to test contamination of clothing. Volunteers then took a predetermined path through the hospital touching commonly used surfaces, such as elevator buttons, along the way. Samples were collected from surfaces that volunteers touched and also from the aprons.

"Based on the user and surface contamination observed following hand drying using high speed air dryers, we question the choice of air dryers in healthcare settings," said Ines Moura, PhD, research fellow, University of Leeds and an author on the study. "Microbes remaining after hand drying can transfer to surfaces via contaminated hands and clothing."

On average, the levels of contamination to surfaces volunteers touched with their hands were 10 times higher after hands were dried with an air dryer than with paper towels. Researchers also saw greater microbial transfer to the apron when volunteers used the air dryer. The transfer of microbes to volunteers' clothing after using the air dryer also contributed to the spread of germs.

"The study was performed in a healthcare setting and has important lessons for health institutions that still have high speed air dryers in restrooms, but the results are also relevant for public restrooms with high foot traffic," Moura said.

Credit: 
Society for Healthcare Epidemiology of America

More than one in 10 patients with lung cancer do not know what type they have

image: More than one in 10 patients with lung cancer do not know what type of tumor they have, according to data from a 17-country study carried out by the Global Lung Cancer Coalition (GLCC) to be presented at the European Lung Cancer Conference (ELCC). Nearly one in five patients surveyed did not feel involved in decisions about their treatment and care, and a similar proportion felt that they had never or only sometimes been treated with dignity and respect by those treating them.

Image: 
ESMO credit

- The increasing complexity of treatments for lung cancer and language differences can make it difficult for patients to communicate with their medical teams

- Risks of jeopardising the treatment and care journey as well as recent progress in patient empowerment.

Lugano, Switzerland; Denver, CO, USA, 17 March 2021 - More than one in 10 patients with lung cancer do not know what type of tumour they have, according to data from a 17-country study carried out by the Global Lung Cancer Coalition (GLCC) to be presented at the European Lung Cancer Conference (ELCC) (1). Nearly one in five patients surveyed did not feel involved in decisions about their treatment and care, and a similar proportion felt that they had never or only sometimes been treated with dignity and respect by those treating them.

"I was shocked that some people didn't know what type of lung cancer they had because, if they didn't have that information, how could they understand their treatment options for making decisions about their care?" said Vanessa Beattie from the GLCC. "Receiving a diagnosis of lung cancer is devastating and it's crucial that patients receive good quality information from the start so they are empowered to make informed decisions about their treatment. At diagnosis, they should be offered information - written or in another form - about their type and stage of cancer and a potential treatment plan which they can discuss with their cancer team and their family."

Of 907 patients with lung cancer who responded to the survey carried out in January 2020, 574 (63%) were from Europe. Of European respondents, 11% did not know what type of lung cancer they had (13% globally), 19% did not feel involved in decisions about their treatment and care (18% globally), and 11% felt they had 'never' or only 'sometimes' been treated with dignity and respect by their treatment team (9% globally).

Beattie suggested that, while cancers services may vary across Europe and globally, clinicians need to keep challenging themselves to drive improvements in lung cancer care and engage with patients to address their individual needs.

"There is still a stigma attached to lung cancer because of its links with smoking, but every patient should be treated with dignity and respect at all times and have a positive experience of care wherever they are treated, including opportunities to talk about their concerns," said Beattie.

Language differences and the increasing complexity of treatments for lung cancer can make it difficult for patients to communicate with their medical team and this may jeopardise not only their care but also recent progress in patient empowerment.

A second study to be presented at ELCC highlights the significant need for interpreters at cancer clinics. Between November 2017 and December 2020, 242 referrals for interpreters speaking a total of 24 languages were arranged at a major hospital in Ireland (2). The majority were for patients from Central and Eastern Europe and the number of interpreter requests ranged from 0-18 per patient. The significant number of referrals reflect the fact that one in six people resident in Ireland were born abroad, and three quarters of these speak their primary language at home, with 20% of those aged 65 and over having little or no English (3).

"A lack of patient understanding of their disease is a major issue especially for those with lung cancer as there have been a lot of recent advances in targeted therapies which patients take at home rather than in hospital. If there is a language barrier, patients may miss appointments or take their medicines incorrectly which can affect their prognosis and quality of life," said lead investigator, Dr Tianna Martin, from Beaumont Hospital, Dublin, Ireland.

She pointed out how easily misunderstandings can occur and stressed the importance of asking patients their preferred language especially when they come from countries where multiple languages are spoken.

"It's really heart-breaking to see a patient who appeared to understand their diagnosis and treatment become deeply distressed weeks or months later when they finally realise they have cancer," she said.

Martin suggested that records of patients with language needs should be flagged 'at risk' so that clinicians check carefully to ensure that appropriate translation services are in place. She also proposed that, given the growing complexity of lung cancer treatments, specialised training should be given to interpreters at cancer clinics.

"It is important that interpreters can accurately explain the diagnosis and treatment options at all stages of the disease so that patients can make really informed decisions and, with the rise in virtual consultations as a result of COVID-19, we need to work out the best approach for overcoming language barriers in that setting too," she concluded.

Commenting on the findings of the two studies, Professor Sanjay Popat, from the Royal Marsden NHS Foundation Trust, London, UK, said that the results should be a wake-up call to all healthcare professionals involved in the care of patients with lung and other cancers to get processes in place to ensure effective communication.

"The statistics from the GLCC survey paint a bleak picture and at least 11% of patients not knowing their type of lung cancer is a very damning statistic. We want patients to be empowered to make decisions about how and where they want to be treated and that can only happen if we have good communication at all stages, with shared aims and goals," he said.

"If we can't get the basics right, it will be very difficult to ensure that patients understand the increasingly complex issues about their treatment options and possible side-effects, particularly the 'red flag' side-effects they need to tell us about immediately," he added.

Popat pointed out that the Dublin research underlines the need for experienced medical translators in an increasingly cosmopolitan society and the importance of 24/7 professional services, especially for patients being treated in hospital.

"The key thing is for everyone to know these translation services exist and to make use of them. Relying on family members to translate is not good practice. We need translators who know how to talk about difficult subjects such as prognosis and end of life care, and can help us understand cultural sensitivities so that we give information in an appropriate way," said Popat.

For patients with lung cancer facing communication or language barriers he highlighted the growing range of patient support groups specialising in providing information and support for specific types of the disease, such as ALK+ and EGFR mutation-positive non-small cell lung cancers.

"In many countries these specialist groups are becoming established to provide a lot of background information about these specific types of lung cancer and the kind of questions patients need to ask and what they should be expecting as part of their care. It all helps to ensure that communication about complex issues is as good as it can be in what is likely to be a very stressful situation for patients," Popat concluded.

Credit: 
European Society for Medical Oncology

Socioeconomic factors play key role in COVID-19 impact on Blacks, Hispanics

image: Blacks, Hispanics more impacted by #COVID-19 due to factors such as income, neighborhood, household size

Image: 
ATS

March 17, 2021-- A new study published online in the Annals of the American Thoracic Society reveals how socioeconomic factors partially explain the increased odds that Black and Hispanic Americans have of testing positive for SARS-CoV-2, the virus that causes COVID-19.

In "Association of Race and Ethnicity With COVID-19 Test Positivity and Hospitalization Is Mediated by Socioeconomic Factors," Hayley B. Gershengorn, MD, associate professor, Division of Pulmonary, Critical Care and Sleep Medicine, University of Miami Miller School of Medicine and co-authors looked at the medical records of 15,473 patients tested and 295 hospitalized with COVID-19 between March 1, 2020 and July 23, 2020 at University of Miami hospitals and clinics. This research was conducted as a retrospective cohort study--one that follows two groups of former patients.

Dr.Gershengorn and colleagues found that the socioeconomic factors of population density at the patient's recorded address, median income, and household size were significantly related to race/ethnicity and explained some of the relation of race/ethnicity with both test positivity and hospitalization. They found no association between race or ethnicity with death rates or other outcomes for hospitalized patients.

"The associations between race/ethnicity and test positivity or hospitalization were not as strong once we adjusted for these socioeconomic factors," she said.

Of patients who were tested for SARS-CoV-2, 29.0 percent were non-Hispanic white, 48.1 percent were Hispanic white, 15.0 percent were non-Hispanic Black, 1.7 percent were Hispanic Black, and 1.6 percent were "other." Among those tested, 1,256 patients (8.1 percent) tested positive and, of the hospitalized patients, 47 (15.9 percent) died. After adjustment for demographics, race/ethnicity was associated with test positivity and hospitalization.

The researchers conducted a mediation analysis to see if household income, population density and household size explained the association of race and ethnicity with COVID-19 outcomes. Mediation analysis is a statistical technique to help explain underlying reasons for an association of an exposure (in this case, race/ethnicity) and an outcome (in this case, test positivity).

"Numerous studies have demonstrated an association of race and/or ethnicity with outcomes (e.g., case positivity, hospitalization, and, sometimes, mortality) in COVID-19," saidDr.Gershengorn. "Specifically, we have seen that, on the whole, non-white and/or Hispanic people tend to fare worse than non-Hispanic white individuals. Appropriately, much has been written about how these associations with worse outcomes almost assuredly have little to do with differences in biology or intrinsic susceptibility to infection across races and ethnicities. Rather, these associations reflect external factors to which minority individuals are more often subject. One of these proposed factors is socioeconomic circumstance; this hypothesis has face validity, but had not been demonstrated in COVID-19. We set out to prove that socioeconomic disparities mediate the association of race and/or ethnicity with worse outcomes in COVID-19."

Of the three socioeconomic factors the researchers examined, they found that median income mediated the largest proportion of COVID-19 positive tests--27 percent. Population density mediated 17 percent and household size mediated 20 percent.

"We found that all three socioeconomic factors were associated with higher odds of test positivity, regardless of race or ethnicity," she stated. "For example, after accounting for other differences, individuals of all races and ethnicities living in the highest population density neighborhoods had 2.5-fold higher odds of test positivity than those living in areas with the lowest population density." Death following hospitalization for COVID-19 was no more common for Black or Hispanic patients than for non-Hispanic white patients.

The researchers believe it would be useful for similar studies to be done in other regions of the U.S.--and parts of the world--with different ethnic/racial makeups and socioeconomic pressures, in order to show the consistency of their findings in other settings and to better understand which (if any) socioeconomic factors impact the association of race and ethnicity with COVID-19 outcomes.

The research team finds it likely that the associations they found between the specific social determinants of health they evaluated and disease risk would be generalizable to other infections with droplet and airborne transmission. Improvements in the social situations of all patients living in more crowded, less well-off communities may pay dividends for their health when the next pandemic, or the next season of influenza, hits.

Dr. Gershengorn adds, "We need to recognize that however much we measure and adjust for potential mediators--socioeconomic factors, access to health care, access to education--we still have structural racism in this country that likely drives many health-related outcomes for minority people. Quantifying the impact of structural racism is important, but more important is working to abolish it."

Credit: 
American Thoracic Society

New software improves accuracy of factories' mass-produced 3D-printed parts

image: The software can detect defects in the printed parts and determine where in the printer the defects occur.

Image: 
University of Illinois Urbana-Champaign

Researchers at University of Illinois Urbana-Champaign developed software to improve the accuracy of 3D-printed parts, seeking to reduce costs and waste for companies using additive manufacturing to mass produce parts in factories.

"Additive manufacturing is incredibly exciting and offers tremendous benefits, but consistency and accuracy on mass-produced 3D-printed parts can be an issue. As with any production technology, parts built should be as close to identical as possible, whether it is 10 parts or 10 million," said Professor Bill King, Andersen Chair in the Department of Mechanical Science and Engineering and leader of the project.

The team's software allows for the rapid and automatic measurement of additively manufactured parts - a processes that is typically time consuming and costly. It also allows for increased accuracy.

"Factories that rely on 3D printing are being built rapidly all over the world. Our software helps ensure production is consistent, accurate, and cost-effective," King said.

The software tracks how the accuracy of an additively manufactured part depends on which printer made the part and where the part was located in the printer. This process works by measuring parts using optical scanning technology and analysis of the scan data. This analysis allows a user to determine which parts are accurate and identifies which printers, and settings, produce the most accurate parts.

Credit: 
University of Illinois Grainger College of Engineering

New software improves accuracy of factories' mass-produced 3D-printed parts

Researchers at University of Illinois Urbana-Champaign developed software to improve the accuracy of 3D-printed parts, seeking to reduce costs and waste for companies using additive manufacturing to mass produce parts in factories.

"Additive manufacturing is incredibly exciting and offers tremendous benefits, but consistency and accuracy on mass-produced 3D-printed parts can be an issue. As with any production technology, parts built should be as close to identical as possible, whether it is 10 parts or 10 million," said Professor Bill King, Andersen Chair in the Department of Mechanical Science and Engineering and leader of the project.

The team's software allows for the rapid and automatic measurement of additively manufactured parts - a processes that is typically time consuming and costly. It also allows for increased accuracy.

"Factories that rely on 3D printing are being built rapidly all over the world. Our software helps ensure production is consistent, accurate, and cost-effective," King said.

The software tracks how the accuracy of an additively manufactured part depends on which printer made the part and where the part was located in the printer. This process works by measuring parts using optical scanning technology and analysis of the scan data. This analysis allows a user to determine which parts are accurate and identifies which printers, and settings, produce the most accurate parts.

Credit: 
University of Illinois Grainger College of Engineering

New quantum algorithm surpasses the QPE norm

image: See image for caption

Image: 
Kenji Sugisaki, Takeji Takui, Kazunobu Sato

OSAKA, Japan. Quantum computers have seen a lot attention recently as they are expected to solve certain problems that are outside the capabilities of normal computers. Primary to these problems is determining the electronic states of atoms and molecules so they can be used more effectively in a variety of industries - from lithium-ion battery designs to in silico technologies in drug development. A common way scientists have approached this problem is by calculating the total energies of the individual states of a molecule or atom and then determine the difference in energy between these states. In nature, many molecules grow in size and complexity, and the cost to calculate this constant flux is beyond the capability of any traditional computer or currently establish quantum algorithms. Therefore, theoretical predictions of the total energies have only been possible if molecules are not sizable and isolated from their natural environment.

"For quantum computers to be a reality, its algorithms must be robust enough to accurately predict the electronic states of atoms and molecules, as they exist in nature, " state Kenji Sugisaki and Takeji Takui from the Graduate School of Science, Osaka City University.

In December 2020, Sugisaki and Takui, together with their colleagues, led a team of researchers to develop a quantum algorithm they call Bayesian eXchange coupling parameter calculator with Broken-symmetry wave functions (BxB), that predicts the electronic states of atoms and molecules by directly calculating the energy differences. They noted that energy differences in atoms and molecules remain constant, regardless to how complex and large they get despite their total energies grow as the system size. "With BxB, we avoided the common practice of calculating the total energies and targeted the energy differences directly, keeping computing costs within polynomial time", they state. "Since then, our goal has been to improve the efficiency of our BxB software so it can predict the electronic sates of atoms and molecules with chemical precision."

Using the computing costs of a well-known algorithm called Quantum Phase Estimation (QPE) as a benchmark, "we calculated the vertical ionization energies of small molecules such as CO, O2, CN, F2, H2O, NH3 within 0.1 electron volts (eV) of precision," states the team, using half the number of qubits, bringing the calculation cost on par with QPE.

Their findings will be published online in the March edition of The Journal of Physical Chemistry Letters.

Ionization energy is one of the most fundamental physical properties of atoms and molecules and an important indicator for understanding the strength and properties of chemical bonds and reactions. In short, accurately predicting the ionization energy allows us to use chemicals beyond the current norm. In the past, it was necessary to calculate the energies of the neutral and ionized states, but with the BxB quantum algorithm, the ionization energy can be obtained in a single calculation without inspecting the individual total energies of the neutral and ionized states. "From numerical simulations of the quantum logic circuit in BxB, we found that the computational cost for reading out the ionization energy is constant regardless of the atomic number or the size of the molecule," the team states, "and that the ionization energy can be obtained with a high accuracy of 0.1 eV after modifying the length of the quantum logic circuit to be less than one tenth of QPE." (See image for modification details)

With the development of quantum computer hardware, Sugisaki and Takui, along with their team, are expecting the BxB quantum algorithm to perform high-precision energy calculations for large molecules that cannot be treated in real time with conventional computers.

Credit: 
Osaka City University

South African Oxford AstraZeneca Covid-19 vaccine study a global game-changer

This is a landmark study in so far as being the first to raise the alarm that, despite early successes with Covid-19 vaccines, further research is warranted on a next generation of Covid-19 vaccines.

The results from this study, however, only indicate that the AstraZeneca vaccine does not have at least 60% efficacy against mild-moderate Covid-19 due to the B.1.351 (N501Y.V2) variant.

Based on a broader body of evidence, the World Health Organization recommends that this vaccine still be deployed in countries where the B.1.351 variant circulates, as it likely still protects against severe infection, hospitalisation, and death caused by Covid-19.

Professor Shabir Madhi, Executive Director of the Vaccines and Infectious Diseases Analytics (VIDA) Research Unit at the University of the Witwatersrand, Johannesburg, led the trial in South Africa:

"Despite the disappointing finding that the AstraZeneca vaccine did not protect against mild Covid infection because of the B.1.351 variant first identified in South Africa, peer review and publication of our research validates the findings and makes a compelling case for the development of a second-generation vaccines worldwide," says Madhi.

First-generation vaccines refer to those designed to respond to the original SARS-CoV-2 virus. Second-generation vaccines refer to technology and design innovations that can provide protections against the constantly evolving variants that cause Covid-19 disease.

A rapid response to variant reality

The findings of this study were previously publicised as a preprint on Sunday, 7 February 2021, and concluded that the ChAdOx1 nCoV-19 vaccine provided minimal protection against mild to moderate Covid-19 infection from the B.1.351 coronavirus variant first identified in South Africa in mid-November 2020.

Prior to the evolution of the B.1.351 and P.1 variants, the South African National Department of Health (NDOH) had ordered and taken delivery of approximately one million doses of the Oxford AstraZeneca vaccine on 1 February 2021, after a published pooled analysis of this vaccine in December 2020 showed an overall vaccine efficacy of 66.7% in the UK and Brazil.

"We were in a state of euphoria about the high efficacy of several Covid-19 vaccines against the original virus, but then the AstraZeneca study threw us a curve-ball," says Madhi. "In this study now published in NEJM, we found that two doses of ChAdOx1 nCoV19 had no efficacy against non-hospitalized mild to moderate Covid-19, mainly due to the B.1.351 variant."

What the SA study published in NEJM reveals

The randomised, multi-centre, double-blinded trial enrolled 2026 participants between 24 June and 9 November 2020.

The trial was a phase 1b/11 trial that aimed to evaluate the safety, immunogenicity, and efficacy of the AstraZeneca vaccine ChAdOx1 nCoV19 in preventing symptomatic Covid-19. Immunogenicity refers to the ability of a foreign substance, such as an antigen, to provoke an immune response. Vaccine efficacy refers to the percentage reduction of a disease in a clinical trial.

"A trial enrolling just 2026 participants is considered small, while phase 3 trials enroll tens of thousands of participants," says Madhi. "Yet the startling data that our small trial generated was irrefutable, and the implications profound."

Profile of a South African AstraZenca Covid-19 vaccine trial participant

The majority of participants enrolled were relatively young (under 65-years-old), generally healthy, and HIV-negative. The median [middle] age of participants was 30 years old. More than half (56.5%) of the trial participants identified as male, 70.5% were Black Africans, 12.8% were white, and 14.9% identified as 'mixed' race.

"These demographics are important because they reflect characteristics of the overall population in South Africa. Conducting clinical trials in diverse settings like these is critical to understanding how vaccines work in local contexts," says Madhi.

Testing a hypothesis

The primary ojective of this trial was to establish this vaccine's efficacy against all-severity Covid-19, irrespective of variants.

A secondary objective was to evaluate the vaccine's efficacy against the B.1.351 variant specifically.

"When this trial began in June 2020, we were testing a vaccine against SARS-COV-2," says Madhi. "By January 2021, SARS-CoV-2 had spawned variants, including the B.1.351 first discovered in South Africa. As a secondary objective, we tested a hypothesis: would this vaccine prove at least 60% efficacious in preventing mild to moderate Covid-19 disease? It did not."

The results showed that a two-dose regimen of ChAdOx1-nCov19 did not show protection against mild to moderate Covid-19 due to the B.1.351 variant.

Crucially, Madhi notes that, "This vaccine may still help protect high-risk individuals with co-morbidities from contracting severe Covid-19 disease, having to be hospitalised, mechanically ventilated, or dying. The AstraZeneca vaccine remains essential in the arsenal against this virus, particularly in Africa, which has already received 14 million doses of this vaccine as the Covid-19 immunization programme starts in multiple countries."

How the WHO took note

On 15 February 2021, the WHO recommended that the AstraZeneca vaccine still be rolled out, even in countries where the B.1.351 variant or other similar variants of concern are circulating.

A WHO news release says that the vaccine was reviewed on 8 February by the WHO Strategic Advisory Group of Experts on Immunization (SAGE), which makes recommendations for vaccines' use in populations (i.e. recommended age groups, intervals between shots, advice for specific groups such as pregnant and lactating women). The SAGE recommended the vaccine for all age groups 18 years and above.

"While the AstraZeneca vaccine - like many other first-generation Covid-19 vaccines - is unlikely to interrupt transmission of SARS-CoV-2 or protect against mild infection from variants like B.1.351, these first-generation vaccines could still provide the only sustainable option to prevent flooding our hospitals with severe Covid-19 cases, and to mitigate Covid-19 deaths once the third wave hits," says Madhi.

Second-generation vaccine innovation

The development of an Oxford AstraZeneca and other Covid-19 vaccines targeting the B.1351 variant is currently underway.

The South African study increased awareness worldwide of the necessity of developing vaccines that target variants specifically - and even reimagining vaccines entirely.

Innovations in vaccine technologies, platforms and designs suggest exciting advances in this field.

"The finding of our [Oxford AstraZeneca Covid-19 vaccine] study are truly a turning point in Covid vaccine development - and a rude awakening," says Madhi. "This one small South African study has alerted the world to the fact that second generation Covid-19 vaccines will be required to provide protection against inevitable and persistent SARS-COV-2 variants. If we had not conducted this trial in South Africa, the world would be none the wiser."

Credit: 
University of the Witwatersrand

PPE supplied to the NHS during COVID-19 pandemic poses challenge to the environment

According to a new study published in the Journal of the Royal Society of Medicine, the carbon footprint of personal protective equipment (PPE) provided to health and social care staff in England during the first six months of the COVID-19 pandemic was equivalent to flying from London to New York 244 times every day. The good news is that adopting a range of strategies including increased UK manufacture, reusing and recycling could reduce the environmental impact of PPE dramatically while maintaining the safety of staff and patients.

The study, by Brighton and Sussex Medical School and Brighton and Sussex University Hospitals NHS Trust, found that the 3 billion items of PPE used from February to July last year generated 591 tonnes of carbon dioxide a day, or 27,000 times the average individual's carbon footprint. The 1.8 billion gloves used had the biggest environmental impact, followed by aprons, face shields and masks.

The study also suggested ways in which PPE use in the future could lessen environmental impact. This includes reusing gowns and face shields where possible, recycling PPE waste, and manufacture of PPE in the UK. But the biggest impact could be through reducing the volumes of PPE used, for example using hand-washing instead of wearing gloves.

Chantelle Rizan, a doctor in the NHS and a research fellow at the Royal College of Surgeons of England, led the study. She said: "COVID-19 has impacted many aspects of life. Ours is the first study to look at the environmental harm of using PPE on such scale, and the results are concerning. However, a combination of strategies could have reduced the carbon footprint by 75%. We are not advocating actions that could increase risk of infection, however, guidelines around use of PPE aren't always consistent or up to date with the latest science. It may be perfectly safe to wash hands rather than use gloves in many situations, and that is something that needs further exploration."

Professor Neil Mortensen, President of the Royal College of Surgeons of England, said: "It's clear the virus will be with us for some time yet, so the need for PPE to keep staff and patients safe is still paramount. But the findings of this new study are sobering, and we must also consider how to reduce the environmental impact of PPE, including making greater use of reusable items or how PPE and other plastic healthcare waste can be recycled - something the College's Sustainability in Surgery working group is looking at."

Credit: 
University of Sussex

New bioink brings 3D-printing of human organs closer to reality

Researchers at Lund University in Sweden have designed a new bioink which allows small human-sized airways to be 3D-bioprinted with the help of patient cells for the first time. The 3D-printed constructs are biocompatible and support new blood vessel growth into the transplanted material. This is an important first step towards 3D-printing organs. The new study has been published in Advanced Materials.

Chronic lung diseases are the third leading cause of death worldwide with an EU cost of more than €380 billion annually. For many chronic diseases there is no cure and the only end-stage option for patients is lung transplantation. However, there are not enough donor lungs to meet clinical demand.

Therefore, researchers are looking at ways to increase the amount of lungs available for transplantation. One approach is fabricating lungs in the lab by combining cells with a bioengineered scaffold.

"We started small by fabricating small tubes, because this is a feature found in both airways and in the vasculature of the lung. By using our new bioink with stem cells isolated from patient airways, we were able to bioprint small airways which had multiple layers of cells and remained open over time", explains Darcy Wagner, Associate Professor and senior author of the study.

The researchers first designed a new bioink (a printable material with cells) for 3D-bioprinting human tissue. The bioink was made by combining two materials: a material derived from seaweed, alginate, and extracellular matrix derived from lung tissue.

This new bioink supports the bioprinted material over several stages of its development towards tissue. They then used the bioink to 3D-bioprint small human airways containing two types of cells found in human airways. However, this bioink can be adapted for any tissue or organ type.

"These next generation bioinks also support the maturation of the airway stem cells into multiple cell types found in adult human airways, which means that less cell types need to be printed, simplifying the nozzle numbers needed to print tissue made of multiple cell types", says Darcy Wagner.

Wagner notes that the resolution needs to be improved to 3D-bioprint more distal lung tissue and the air sacks, known as alveoli, that are vital for gas exchange.

"We hope that further technological improvements of available 3D printers and further bioink advances will allow for bioprinting at a higher resolution in order to engineer larger tissues which could be used for transplantation in the future. We still have a long way to go", she says.

The team used a mouse model closely resembling the immunosuppression used in patients undergoing organ transplantation. When transplanted, they found that 3D-printed constructs made from the new bioink were well-tolerated and supported new blood vessels.

"The development of this new bioink is a significant step forward, but it is important to further validate the functionality of the small airways over time and to explore the feasibility of this approach in large animal models", concludes Martina De Santis, the first author of the study.

Credit: 
Lund University